A few short months following the launch of the new brand, Merck & Co. acquired IDENIX for $3.85 billion.
Case study · 24
Idenix Pharmaceuticals
IDENIX is a biopharmaceutical company focused on the treatment of hepatitis C virus (HCV) infections.
Brand identity
Brand identity




